Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:AKRO NASDAQ:CRNX NASDAQ:IMNM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$88.85-3.8%$76.80$47.86▼$107.37$5.12B0.31562,541 shs771,576 shsAKROAkero Therapeutics$53.66+0.1%$47.41$21.34▼$58.40$4.29B-0.293.89 million shs2.24 million shsCRNXCrinetics Pharmaceuticals$42.31-4.2%$35.59$24.10▼$62.53$4.16B0.332.22 million shs1.46 million shsIMNMImmunome$16.49+0.9%$10.90$5.15▼$17.08$1.42B1.941.90 million shs1.34 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+5.77%+4.62%+22.83%+30.19%+2.74%AKROAkero Therapeutics-0.39%+15.29%+25.09%-1.34%+79.08%CRNXCrinetics Pharmaceuticals+0.23%-0.63%+30.74%+33.71%-23.35%IMNMImmunome+15.96%+16.70%+72.47%+56.46%+34.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$88.85-3.8%$76.80$47.86▼$107.37$5.12B0.31562,541 shs771,576 shsAKROAkero Therapeutics$53.66+0.1%$47.41$21.34▼$58.40$4.29B-0.293.89 million shs2.24 million shsCRNXCrinetics Pharmaceuticals$42.31-4.2%$35.59$24.10▼$62.53$4.16B0.332.22 million shs1.46 million shsIMNMImmunome$16.49+0.9%$10.90$5.15▼$17.08$1.42B1.941.90 million shs1.34 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+5.77%+4.62%+22.83%+30.19%+2.74%AKROAkero Therapeutics-0.39%+15.29%+25.09%-1.34%+79.08%CRNXCrinetics Pharmaceuticals+0.23%-0.63%+30.74%+33.71%-23.35%IMNMImmunome+15.96%+16.70%+72.47%+56.46%+34.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 2.87Moderate Buy$113.2327.44% UpsideAKROAkero Therapeutics 2.31Hold$73.3836.74% UpsideCRNXCrinetics Pharmaceuticals 2.71Moderate Buy$74.4575.97% UpsideIMNMImmunome 2.82Moderate Buy$23.2040.69% UpsideCurrent Analyst Ratings BreakdownLatest IMNM, ACLX, AKRO, and CRNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/16/2025ACLXArcellxStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$129.0010/10/2025AKROAkero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$72.00 ➝ $54.0010/10/2025AKROAkero TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/10/2025AKROAkero TherapeuticsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/10/2025AKROAkero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$72.00 ➝ $54.0010/10/2025AKROAkero TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Hold10/9/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$88.0010/9/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$88.0010/9/2025AKROAkero TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/9/2025AKROAkero TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$75.00 ➝ $56.0010/9/2025AKROAkero TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$73.00 ➝ $54.00(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M45.65N/AN/A$8.41 per share10.56AKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/ACRNXCrinetics Pharmaceuticals$1.04M3,831.50N/AN/A$14.29 per share2.96IMNMImmunome$9.04M158.77N/AN/A$2.27 per share7.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$3.42N/AN/AN/A-329.93%-43.04%-27.41%11/6/2025 (Estimated)AKROAkero Therapeutics-$252.06M-$2.00N/AN/AN/AN/A-15.84%-14.59%11/14/2025 (Estimated)CRNXCrinetics Pharmaceuticals-$298.41M-$4.11N/AN/AN/AN/A-32.28%-29.45%11/6/2025 (Estimated)IMNMImmunome-$292.96M-$3.08N/AN/AN/A-1,687.08%-76.10%-65.14%11/12/2025 (Estimated)Latest IMNM, ACLX, AKRO, and CRNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025IMNMImmunome-$0.57N/AN/AN/A$0.73 millionN/A11/6/2025Q3 2025ACLXArcellx-$1.00N/AN/AN/A$11.24 millionN/A11/6/2025Q3 2025CRNXCrinetics Pharmaceuticals-$1.27N/AN/AN/A$0.39 millionN/A8/8/2025Q2 2025AKROAkero Therapeutics-$0.97-$0.86+$0.11-$0.86N/AN/A8/7/2025Q2 2025ACLXArcellx-$1.03-$0.94+$0.09-$0.94$16.76 million$7.55 million8/7/2025Q2 2025CRNXCrinetics Pharmaceuticals-$1.13-$1.23-$0.10-$1.23$0.52 million$1.03 million8/6/2025Q2 2025IMNMImmunome-$0.52-$0.50+$0.02-$0.50$1.03 million$4.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AAKROAkero TherapeuticsN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A3.813.81AKROAkero Therapeutics0.0212.6612.66CRNXCrinetics PharmaceuticalsN/A17.8017.80IMNMImmunomeN/A12.1312.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%AKROAkero TherapeuticsN/ACRNXCrinetics Pharmaceuticals98.51%IMNMImmunome44.58%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%AKROAkero Therapeutics7.07%CRNXCrinetics Pharmaceuticals4.60%IMNMImmunome7.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.46 million50.83 millionOptionableAKROAkero Therapeutics3079.99 million74.33 millionOptionableCRNXCrinetics Pharmaceuticals21094.18 million89.84 millionOptionableIMNMImmunome4087.04 million80.35 millionOptionableIMNM, ACLX, AKRO, and CRNX HeadlinesRecent News About These CompaniesImmunome (NASDAQ:IMNM) Reaches New 52-Week High - Time to Buy?October 16 at 3:18 PM | marketbeat.comWeiss Ratings Reiterates Sell (D-) Rating for Immunome (NASDAQ:IMNM)October 9, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Trading Up 11.5% - What's Next?October 6, 2025 | marketbeat.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2025 | businesswire.comStocks With Rising Relative Strength: ImmunomeSeptember 27, 2025 | msn.comWill Immunome's (IMNM) Antibody Collaboration Refocus Its Pipeline Expansion Strategy?September 27, 2025 | finance.yahoo.comImmunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of "Buy" by AnalystsSeptember 27, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Stock Price Down 5.9% - Here's WhySeptember 25, 2025 | marketbeat.comImmunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains?September 25, 2025 | zacks.comImmunome (NASDAQ:IMNM) Shares Up 8% - What's Next?September 23, 2025 | marketbeat.comImmunome stock a ‘buy' on ‘rich pipeline' of oncology therapeutics: analystsSeptember 23, 2025 | proactiveinvestors.comImmunome stock a ‘buy' on ‘rich pipeline' of oncology therapeutics: analystsSeptember 23, 2025 | proactiveinvestors.comImmunome (NASDAQ:IMNM) Upgraded to "Strong-Buy" at The Goldman Sachs GroupSeptember 23, 2025 | marketbeat.comImmunome initiated with a Buy at Goldman SachsSeptember 23, 2025 | msn.comGoldman Sachs Initiates Coverage of Immunome (IMNM) with Buy RecommendationSeptember 23, 2025 | msn.comGoldman Sachs Group Inc. Lowers Holdings in Immunome, Inc. $IMNMSeptember 21, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Down 5.4% - What's Next?September 20, 2025 | marketbeat.comWedbush Reiterates Outperform Rating for Immunome (NASDAQ:IMNM)September 19, 2025 | marketbeat.comInfinimmune Announces Research Collaboration with ImmunomeSeptember 18, 2025 | businesswire.comCraig-Hallum Initiates Coverage of Immunome (IMNM) with Buy RecommendationSeptember 6, 2025 | msn.comImmunome initiated with a Buy at Craig-Hallum ahead of near-term catalystsSeptember 5, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMNM, ACLX, AKRO, and CRNX Company DescriptionsArcellx NASDAQ:ACLX$88.85 -3.52 (-3.81%) Closing price 04:00 PM EasternExtended Trading$88.83 -0.02 (-0.02%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Akero Therapeutics NASDAQ:AKRO$53.66 +0.06 (+0.11%) Closing price 04:00 PM EasternExtended Trading$53.66 0.00 (-0.01%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Crinetics Pharmaceuticals NASDAQ:CRNX$42.31 -1.84 (-4.17%) Closing price 04:00 PM EasternExtended Trading$42.50 +0.18 (+0.44%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Immunome NASDAQ:IMNM$16.49 +0.14 (+0.86%) Closing price 04:00 PM EasternExtended Trading$16.33 -0.16 (-0.97%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Buys Rival's Patent Treasure Trove in Strategic Move Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
